Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2018-03-06 Board/Management Inform…
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes announcements of changes in the company's board of directors, including appointments and compensation details, as well as a corporate name change. There are no financial statements or detailed financial performance data present. The primary focus is on management and board changes, which aligns with the category for announcements of changes in the company's board or senior management. Therefore, the appropriate classification is 'Board/Management Information' (MANG). The document length is about 4896 characters, which is sufficient to contain substantive information rather than a brief announcement or certification. Hence, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2018-03-06 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 16, 2018. It details the completion of an acquisition (merger) of Enochian Biopharma by DanDrit Biotech USA, Inc., including the issuance of shares, private placements, and related agreements. The content focuses on the acquisition transaction, private placements of equity securities, and related corporate events. There are no financial statements or quarterly/yearly financial results presented, nor is this a proxy, earnings release, or management discussion. The document is a regulatory filing reporting a material corporate event (acquisition and financing) rather than a full financial report or earnings announcement. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2018-02-23 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2018
2018-02-09 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 18, 2018. The content primarily announces the appointment of two individuals to the company's Scientific Advisory Board. There are no financial statements, earnings data, or detailed management discussion. The document is short (3024 characters) and includes a press release as an exhibit. This type of filing is a regulatory announcement of a corporate event rather than a financial report or detailed management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2018-01-18 English
CURRENT REPORT
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 12, 2018, by Dandrit Biotech USA, Inc. It announces the entry into a material definitive agreement, specifically an Agreement and Plan of Merger involving the company and Enochian Biopharma, Inc. The document details the terms of the merger agreement, conditions precedent, and related agreements such as license agreements and investor rights agreements. It also includes a press release about the merger. The Form 8-K is a current report used to announce major events that shareholders should know about, including mergers and acquisitions. This filing is not a full annual or quarterly report, nor is it an earnings release or proxy statement. It is a regulatory announcement of a significant corporate transaction, specifically a merger. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under the category 'M&A Activity' with code TAR. Therefore, the correct classification is TAR with high confidence.
2018-01-17 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2018
2017-11-20 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.